Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy

  • Authors:
    • Yoshiko Okita
    • Yoshitaka Narita
    • Yasuji Miyakita
    • Ruriko Miyahara
    • Makoto Ohno
    • Masamichi Takahashi
    • Masahiro Nonaka
    • Yonehiro Kanemura
    • Shin Nakajima
    • Toshiyuki Fujinaka
  • View Affiliations

  • Published online on: July 19, 2016     https://doi.org/10.3892/mco.2016.962
  • Pages: 179-185
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemoradiotherapy for primary central nervous system lymphoma (PCNSL) is associated with a considerable risk of long-term neurotoxicity. The present study aimed to assess the health-related quality of life (HRQOL) of outpatients with PCNSL who have received radiotherapy and high-dose methotrexate (HDMTX) chemotherapy, and to determine the factors that cause a decline in HRQOL and interfere with home living. A total of 37 patients were surveyed 0.9‑14.2 years after their initial diagnosis and treatment. Each patient completed a multi‑part HRQOL questionnaire that was used to examine the associations of HRQOL scores with leukoencephalopathy, Karnofsky performance status (KPS) scores, age, history of recurrence and HDMTX-based chemoradiotherapy. The results demonstrated that the history of recurrence, number of cycles of MTX chemotherapy and age affected the development of leukoencephalopathy. Reductions in KPS score were associated with a history of recurrence (P=0.03), but not with leukoencephalopathy (P=0.8). KPS score, leukoencephalopathy and age were significantly associated with a decline in HRQOL score. A decline in the HRQOL associated with a reduction in KPS score was also observed by multivariate analyses. Deterioration of the HRQOL among outpatients with PCNSL post-chemoradiotherapy was significantly associated with older age (≥66 years) and decreased KPS score. Older patients with a history of recurrence had a higher risk for deteriorated QOL due to development of leukoencephalopathy. Therefore, it is recommended that clinicians monitor the KPS score among outpatients with PCNSL. QOL examination for older patients with a lower KPS score was found to be particularly important for identifying any obstacles for home living.
View References

Related Articles

Journal Cover

September-2016
Volume 5 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Okita Y, Narita Y, Miyakita Y, Miyahara R, Ohno M, Takahashi M, Nonaka M, Kanemura Y, Nakajima S, Fujinaka T, Fujinaka T, et al: Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. Mol Clin Oncol 5: 179-185, 2016
APA
Okita, Y., Narita, Y., Miyakita, Y., Miyahara, R., Ohno, M., Takahashi, M. ... Fujinaka, T. (2016). Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. Molecular and Clinical Oncology, 5, 179-185. https://doi.org/10.3892/mco.2016.962
MLA
Okita, Y., Narita, Y., Miyakita, Y., Miyahara, R., Ohno, M., Takahashi, M., Nonaka, M., Kanemura, Y., Nakajima, S., Fujinaka, T."Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy". Molecular and Clinical Oncology 5.3 (2016): 179-185.
Chicago
Okita, Y., Narita, Y., Miyakita, Y., Miyahara, R., Ohno, M., Takahashi, M., Nonaka, M., Kanemura, Y., Nakajima, S., Fujinaka, T."Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy". Molecular and Clinical Oncology 5, no. 3 (2016): 179-185. https://doi.org/10.3892/mco.2016.962